📊 CTSO Key Takeaways
Is Cytosorbents Corp (CTSO) a Good Investment?
Cytosorbents demonstrates strong revenue growth (+14.5% YoY) and excellent gross margins (70.7%), indicating viable product-market fit. However, the company is deeply unprofitable with negative operating margins (-37.2%), burning cash operationally (-$7.6M), and faces elevated leverage (1.61x D/E) that constrains financial flexibility during a critical growth phase.
Cytosorbents shows decent top-line growth and strong gross margins, but the business remains structurally unprofitable at the operating level and is consuming cash. The balance sheet still supports near-term operations, yet elevated leverage, negative free cash flow, and thin equity make the growth profile lower quality until operating losses narrow materially.
Why Buy Cytosorbents Corp Stock? CTSO Key Strengths
- Revenue growth of 14.5% YoY demonstrates market demand for products
- Exceptional gross margin of 70.7% reflects pricing power and operational efficiency at production level
- Adequate near-term liquidity with current ratio of 2.11x and $7.5M cash
- Revenue grew 14.5% year over year, indicating continued commercial demand
- Gross margin of 70.7% suggests attractive product-level economics
- Current ratio of 2.11x and quick ratio of 1.71x provide reasonable near-term liquidity
CTSO Stock Risks: Cytosorbents Corp Investment Risks
- Persistent operating losses (-$10.4M) and negative net income despite revenue growth signal inability to control operating expenses
- Negative operating cash flow (-$7.6M) indicates business is not self-sustaining and burning capital to fund operations
- High leverage (1.61x D/E) with $14.6M long-term debt limits financial flexibility and increases refinancing risk as cash depletes
- No insider buying activity in past 90 days suggests management lacks confidence despite operational challenges
- Operating margin of -37.2% shows the company is still far from sustainable profitability
- Free cash flow of -7.61M and negative operating cash flow indicate ongoing cash burn
- Debt-to-equity of 1.61x with only 9.02M of equity leaves limited balance-sheet flexibility
Key Metrics to Watch
- Path to operating profitability and operating margin improvement trajectory
- Operating cash flow inflection point and cash burn rate sustainability
- Debt refinancing risks and covenant compliance given deteriorating operational metrics
- Operating cash flow and free cash flow trend
- Operating margin improvement versus revenue growth
Cytosorbents Corp (CTSO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.11x current ratio provides a solid financial cushion.
CTSO Profit Margin, ROE & Profitability Analysis
CTSO vs Healthcare Sector: How Cytosorbents Corp Compares
How Cytosorbents Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cytosorbents Corp Stock Overvalued? CTSO Valuation Analysis 2026
Based on fundamental analysis, Cytosorbents Corp shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cytosorbents Corp Balance Sheet: CTSO Debt, Cash & Liquidity
CTSO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cytosorbents Corp's revenue has declined by 14% over the 5-year period, indicating business contraction. The most recent EPS of $-0.38 indicates the company is currently unprofitable.
CTSO Revenue Growth, EPS Growth & YoY Performance
CTSO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $8.6M | -$2.7M | $-0.04 |
| Q2 2025 | $8.8M | $469.0K | $0.01 |
| Q1 2025 | $8.7M | -$1.5M | $-0.02 |
| Q3 2024 | $8.8M | -$2.3M | $-0.04 |
| Q2 2024 | $9.4M | -$4.1M | $-0.08 |
| Q1 2024 | $9.4M | -$6.4M | $-0.12 |
| Q3 2023 | $8.1M | -$9.2M | $-0.21 |
| Q2 2023 | $8.5M | -$6.2M | $-0.14 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cytosorbents Corp Dividends, Buybacks & Capital Allocation
CTSO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cytosorbents Corp (CIK: 0001175151)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CTSO
What is the AI rating for CTSO?
Cytosorbents Corp (CTSO) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CTSO's key strengths?
Claude: Revenue growth of 14.5% YoY demonstrates market demand for products. Exceptional gross margin of 70.7% reflects pricing power and operational efficiency at production level. ChatGPT: Revenue grew 14.5% year over year, indicating continued commercial demand. Gross margin of 70.7% suggests attractive product-level economics.
What are the risks of investing in CTSO?
Claude: Persistent operating losses (-$10.4M) and negative net income despite revenue growth signal inability to control operating expenses. Negative operating cash flow (-$7.6M) indicates business is not self-sustaining and burning capital to fund operations. ChatGPT: Operating margin of -37.2% shows the company is still far from sustainable profitability. Free cash flow of -7.61M and negative operating cash flow indicate ongoing cash burn.
What is CTSO's revenue and growth?
Cytosorbents Corp reported revenue of $27.8M.
Does CTSO pay dividends?
Cytosorbents Corp does not currently pay dividends.
Where can I find CTSO SEC filings?
Official SEC filings for Cytosorbents Corp (CIK: 0001175151) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CTSO's EPS?
Cytosorbents Corp has a diluted EPS of $-0.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CTSO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cytosorbents Corp has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CTSO stock overvalued or undervalued?
Valuation metrics for CTSO: ROE of -29.9% (sector avg: 15%), net margin of -9.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CTSO stock in 2026?
Our dual AI analysis gives Cytosorbents Corp a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CTSO's free cash flow?
Cytosorbents Corp's operating cash flow is $-7.6M, with capital expenditures of $56.0K. FCF margin is -27.3%.
How does CTSO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -9.7% (avg: 12%), ROE -29.9% (avg: 15%), current ratio 2.11 (avg: 2).
Is Cytosorbents Corp carrying too much debt?
CTSO has a debt-to-equity ratio of 1.61x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 2.11 suggests adequate short-term liquidity.